Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes
Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang · 2026
Read Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes by Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271928.txt.
Description
Wancheng Guo and coauthors compare in 2026 two diabetes drug families for liver health in people who also have fatty liver disease. Both drug types lower blood sugar, yet their effects on liver enzymes may differ. The team used hospital records from 2020 to 2024 across several centers.
After matching patients on starting traits, 243 pairs remained for a fair comparison over six months. The SGLT-2 inhibitor group showed larger drops in two liver enzymes, ALT and AST, than the GLP-1 drug group. Other metabolic measures were also tracked over the same period. The findings give doctors comparative data when liver health weighs into diabetes drug choice.
Catalog record
| CREATOR | Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |